{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:29:13Z","timestamp":1778048953547,"version":"3.51.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s00345-009-0382-4","type":"journal-article","created":{"date-parts":[[2009,2,13]],"date-time":"2009-02-13T10:41:27Z","timestamp":1234521687000},"page":"337-342","source":"Crossref","is-referenced-by-count":31,"title":["Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer"],"prefix":"10.1007","volume":"27","author":[{"given":"Kees","family":"Hendricksen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine G.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik B.","family":"Cornel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henk","family":"Vergunst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theo M.","family":"de Reijke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"van Boven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert A. H. J.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv","family":"Puri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigrid","family":"Gruijs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Alfred","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,2,13]]},"reference":[{"key":"382_CR1","first-page":"2","volume-title":"Guidelines on TaT1 (Non-muscle invasive) Bladder Cancer. Guidelines European Association of Urology","author":"M Babjuk","year":"2008","unstructured":"Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, B\u00f6hle A, Palou J (2008) Guidelines on TaT1 (Non-muscle invasive) Bladder Cancer. Guidelines European Association of Urology. Drukkerij Gelderland BV, Arnhem, pp 2\u201321"},{"key":"382_CR2","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","volume":"178","author":"MC Hall","year":"2007","unstructured":"Hall MC, Chang SS, Dalbagni G et al (2007) Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178:2314\u20132330. doi: 10.1016\/j.juro.2007.09.003","journal-title":"J Urol"},{"key":"382_CR3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:465\u2013466. doi: 10.1016\/j.eururo.2005.12.031","journal-title":"Eur Urol"},{"key":"382_CR4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3727\/095535491820873164","volume":"3","author":"MI Walton","year":"1991","unstructured":"Walton MI, Smith PJ, Workman P (1991) The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun 3:199\u2013206","journal-title":"Cancer Commun"},{"key":"382_CR5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/bjc.1992.73","volume":"65","author":"RM Phillips","year":"1992","unstructured":"Phillips RM, Hulbert PB, Bibby MC et al (1992) In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity. Br J Cancer 65:359\u2013364","journal-title":"Br J Cancer"},{"key":"382_CR6","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/01.ju.0000146274.85012.e1","volume":"173","author":"AG Heijden van der","year":"2005","unstructured":"van der Heijden AG, Verhaegh G, Jansen CF et al (2005) Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol 173:1375\u20131380. doi: 10.1097\/01.ju.0000146274.85012.e1","journal-title":"J Urol"},{"key":"382_CR7","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.juro.2006.06.007","volume":"176","author":"AG Heijden van der","year":"2006","unstructured":"van der Heijden AG, Moonen PM, Cornel EB et al (2006) Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol 176:1349\u20131353. doi: 10.1016\/j.juro.2006.06.007","journal-title":"J Urol"},{"key":"382_CR8","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.juro.2006.06.047","volume":"176","author":"R Puri","year":"2006","unstructured":"Puri R, Palit V, Loadman PM et al (2006) Phase I\/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer. J Urol 176:1344\u20131348. doi: 10.1016\/j.juro.2006.06.047","journal-title":"J Urol"},{"key":"382_CR9","doi-asserted-by":"crossref","unstructured":"Jain A, Phillips RM, Scally AJ et al (2009) Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates. Accepted for publication in J Urol","DOI":"10.1016\/j.urology.2007.12.062"},{"key":"382_CR10","volume-title":"Histological typing of urinary bladder tumours. International classification of tumors 10","author":"FK Mostofi","year":"1973","unstructured":"Mostofi FK, Torloni H, Sobin LH (1973) Histological typing of urinary bladder tumours. International classification of tumors 10. World Health Organization, Geneva"},{"key":"382_CR11","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9","volume":"80","author":"LH Sobin","year":"1997","unstructured":"Sobin LH, Fleming ID (1997) TNM classification of malignant tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 80:1803\u20131804. doi: 10.1002\/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9","journal-title":"Cancer"},{"key":"382_CR12","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1464-410X.1996.09002.x","volume":"77","author":"AP Meijden van der","year":"1996","unstructured":"van der Meijden AP, Hall RR, Kurth KH et al (1996) Phase II trials in Ta, T1 bladder cancer. The marker tumour concept. Br J Urol 77:634\u2013637","journal-title":"Br J Urol"},{"issue":"Suppl 2","key":"382_CR13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1442-2042.1995.tb00476.x","volume":"2","author":"DL Lamm","year":"1995","unstructured":"Lamm DL, van der Meijden AP, Akaza H et al (1995) Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? Int J Urol 2(Suppl 2):23\u201335. doi: 10.1111\/j.1442-2042.1995.tb00476.x","journal-title":"Int J Urol"},{"key":"382_CR14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000473784","volume":"29","author":"AV Bono","year":"1996","unstructured":"Bono AV, Hall RR, Denis L et al (1996) Chemoresection in Ta-T1 bladder cancer. Members of the EORTC genito-urinary group. Eur Urol 29:385\u2013390","journal-title":"Eur Urol"},{"key":"382_CR15","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0090-4295(97)00625-0","volume":"51","author":"M Brausi","year":"1998","unstructured":"Brausi M, Campo B, Pizzocaro G et al (1998) Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative phase II study. Urology 51:506\u2013509. doi: 10.1016\/S0090-4295(97)00625-0","journal-title":"Urology"},{"key":"382_CR16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1159\/000052521","volume":"39","author":"DW Newling","year":"2001","unstructured":"Newling DW, Hetherington J, Sundaram SK et al (2001) The use of valrubicin for the chemoresection of superficial bladder cancer: a marker lesion study. Eur Urol 39:643\u2013647. doi: 10.1159\/000052521","journal-title":"Eur Urol"},{"key":"382_CR17","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.eururo.2006.08.038","volume":"51","author":"M Maffezzini","year":"2007","unstructured":"Maffezzini M, Campodonico F, Canepa G et al (2007) Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1\u2013G2, low- or intermediate-risk, transitional cell carcinoma of the bladder. Eur Urol 51:956\u2013961. doi: 10.1016\/j.eururo.2006.08.038","journal-title":"Eur Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-009-0382-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T00:44:18Z","timestamp":1558140258000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-009-0382-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,13]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["382"],"URL":"https:\/\/doi.org\/10.1007\/s00345-009-0382-4","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,13]]}}}